![](/images/graphics-bg.png)
Real-Life Outcome in Multiple Sclerosis in the Czech Republic
المؤلفون المشاركون
Kobelt, Gisela
Jönsson, Linus
Pavelcova, Miluse
Havrdova, Eva
المصدر
Multiple Sclerosis International
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-02-18
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Background.
Cohort studies and registries provide opportunities to estimate long-term outcome in multiple sclerosis.
Objectives.
To describe changes in disability (EDSS), relapse activity, and health care consumption over the period 2008-2015 by combining two Czech cost-of-illness studies with disease data from the MS Center in Prague.
Methods.
The combined dataset included 426 patients with a mean observation time of 8.3 years.
A Cox proportional hazards model with time-varying covariates for treatment, disease course, and EDSS was applied to estimate the effect of treatment on the risk of progression to EDSS 4 and the risk of relapses.
The use of health care resources (hospitalization, consultation, and tests) was compared between the two cross-sectional studies.
Results.
Total health care costs appeared stable between 2008 and 2015, despite more intense use of disease-modifying treatments in 2015 (52% of patients versus 31% in 2008).
39% of patients starting treatment at EDSS 0-3 in 2008 progressed to EDSS 4 or higher by 2015, while 65% of patients starting at EDSS 0-2 remained stable.
The number of relapses was associated with a higher risk of progression.
In a marginal structural Cox model of the relapse risk, treatment with natalizumab or fingolimod was associated with a lower risk of relapse (hazard ratio 0.68, p<0.01).
Treatment with natalizumab or fingolimod was associated with a lower risk of progression to EDSS 4.
Conclusion.
Our results link relapses to progression and indicate that the newer treatments have a better effectiveness, despite difficulties caused by small a sample size, administrative rules guiding treatment, and absence of a random comparator group.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kobelt, Gisela& Jönsson, Linus& Pavelcova, Miluse& Havrdova, Eva. 2019. Real-Life Outcome in Multiple Sclerosis in the Czech Republic. Multiple Sclerosis International،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1200928
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kobelt, Gisela…[et al.]. Real-Life Outcome in Multiple Sclerosis in the Czech Republic. Multiple Sclerosis International No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1200928
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kobelt, Gisela& Jönsson, Linus& Pavelcova, Miluse& Havrdova, Eva. Real-Life Outcome in Multiple Sclerosis in the Czech Republic. Multiple Sclerosis International. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1200928
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1200928
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)